Author: admin

TITUSVILLE, N.J., November 21, 2025 – The Auτonomy proof-of-concept study was a first-of-its-kind precision approach to evaluating targeted intervention in early Alzheimer’s disease. Following a scheduled review that determined posdinemab did not achieve statistical significance in slowing clinical decline, the Auτonomy study will be discontinued.

The initial findings underscore the deep complexity of the disease, and together with the forthcoming analyses, will offer valuable insights that will shape ongoing and future research as the understanding of Alzheimer’s biology evolves. A full evaluation of the data will be shared with the scientific community in due course.

For nearly three decades, Johnson & Johnson has made meaningful progress to advance scientific understanding of Alzheimer’s disease. We remain committed to transforming the future of Alzheimer’s care and confident in our pioneering pipeline of therapies to treat the broad spectrum of disease. We extend our deepest gratitude to the patients, caregivers, investigators, and clinical trial site teams who participated in the Auτonomy trial.